DNAH9

dynein axonemal heavy chain 9

This gene encodes the heavy chain subunit of axonemal dynein, a large multi-subunit molecular motor. Axonemal dynein attaches to microtubules and hydrolyzes ATP to mediate the movement of cilia and flagella. The gene expresses at least two transcript variants; additional variants have been described, but their full length nature has not been determined.

provided by RefSeq

Biological Domains

Structural Stabilization, Synapse

Pharos Class

Tbio

Also known as

ENSG00000007174 (Ensembl Release 115)

UNIPROTKB Q9NYC9

CILD40, DNAH17L, DNEL1, DYH9, Dnahc9, HL-20, HL20

Summary of Evidence

This tab shows an overview of how the selected gene is associated with AD.

  • Genetic Association with LOAD

    Indicates whether or not this gene shows significant genetic association with Late Onset AD (LOAD) based on evidence from multiple studies compiled by the ADSP Gene Verification Committee
    False

  • Brain eQTL

    Indicates whether or not this gene locus has a significant expression Quantitative Trait Locus (eQTL) based on an AMP-AD consortium study
    True

  • RNA Expression Change in AD Brain

    Indicates whether or not this gene shows significant differential expression in at least one brain region based on AMP-AD consortium work. See ‘EVIDENCE’ tab.
    True

  • Protein Expression Change in AD Brain

    Indicates whether or not this gene shows significant differential protein expression in at least one brain region based on AMP-AD consortium work. See ‘EVIDENCE’ tab.
    False

  • Nominated Target

    Indicates whether or not this gene has been submitted as a nominated target to Agora.
    False

AD Risk Scores

About AD Risk Scores

The TREAT-AD Center at Emory-Sage-SGC has developed a Target Risk Score (TRS) to objectively rank the potential involvement of specific genes in AD. The TRS is derived by summing two component risk scores, the Genetic Risk Score and the Multi-omic Risk Score, each of which is derived from a meta-analysis of multiple harmonized data sets. More information about the methodology used to define these risk scores is available here.

AD Risk Scores for DNAH9

The TRS for DNAH9, along with the component Genetic and Multi-omic Risk Scores, is shown here. The scores for DNAH9 are superimposed on the genome-wide score distributions. If No Data is Currently Available is displayed for a score, that score was not calculated for DNAH9.

Biological Domain Classification

About Biological Domains

A biological domain represents a standardized area of biology defined by a set of discrete, biologically coherent GO terms. The TREAT-AD Center at Emory-Sage-SGC has defined nineteen biological domains associated with AD, and objectively mapped genes to those biological domains using GO term annotations. More information about the methodology used to define AD biological domains, and to generate genome-wide biological domain mappings, is available here.

Biological Domains for DNAH9

Select a biological domain on the left to see the list of GO terms that link DNAH9 to it on the right. The percentage value displayed next to the currently selected biological domain indicates the proportion of DNAH9's total unique GO terms that map to the biological domain. The ratio displayed on the right indicates how many of the biological domain's total GO terms DNAH9 is annotated with.